Allosteric Chromenone Inhibitors for Selective PI3Kα Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3Kα inhibitors are nearly equipotent to wild-type and mutant PI3Kα, lacking selectivity, which limits their therapeutic window and efficacy due to compensatory insulin and glucose production, necessitating the development of inhibitors that selectively target mutant PI3Kα over wild-type to minimize toxicities and enhance antineoplastic effects.
Innovation Solution
Design and use of novel allosteric chromenone inhibitors that target a peripheral binding pocket near known mutations, such as H1047R, to selectively inhibit mutant PI3Kα, thereby reducing systemic metabolic effects and allowing higher drug doses for more complete inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3Kα inhibitors are used, then PI3Kα activity is inhibited, but both wild-type and mutant PI3Kα are inhibited equally (lack of selectivity), causing compensatory insulin and glucose production and limiting therapeutic window
Solution Approach 1:
The invention targets a specific local region (peripheral binding pocket) near the H1047R mutation site in PI3Kα, rather than the general active site. This localized targeting approach allows selective inhibition of mutant PI3Kα while sparing wild-type enzyme, thereby resolving the contradiction between inhibition efficacy and metabolic side effects
Solution Approach 2:
The invention changes the binding parameters by targeting a different binding pocket (peripheral vs. active site) and exploiting mutation-induced structural changes. The chromenone compounds bind to altered conformational states created by mutations like H1047R, achieving selective inhibition based on parameter changes in the mutant enzyme
2Productivity
If higher doses of PI3Kα inhibitors are administered, then more complete inhibition is achieved, but toxicities increase due to wild-type PI3Kα inhibition
Solution Approach 1:
By focusing inhibition on the mutant-specific peripheral binding pocket rather than the conserved active site, the invention achieves high inhibition efficacy for mutant PI3Kα at lower doses, avoiding the toxicities associated with high-dose wild-type inhibition
Solution Approach 2:
The invention applies partial action by selectively targeting only the mutant form of PI3Kα, achieving sufficient inhibition efficacy without the excessive action required to inhibit wild-type enzyme, thereby reducing toxicities
Data Source
AI summary
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I):or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.